Biotransplant, Inc.

Universitè Catholique De Louvain

Mary E White-Scharf

Dominique Latinne

Ruth A Kaplan

Thomas Kieber-Emmons

Christina E Postema

Herve Bazin

Hervé Bazin

Sonny Abraham

Michel G Awwad

James A Hope

The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation

Methods of inhibiting T cell mediated immune responses with humanized

Disclosed are a composition and method for determining the levels of specific immune responsiveness to a glycoprotein in an individual being treated therewith by (i) contacting a body fluid sample obtained from the individual prior to glycoprotein treatment with glycoprotein that has been modified to have an oxidized carbohydrate portion; (ii) contacting a body fluid sample obtained from the individual subsequent to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion; and (iii) observing the degree of difference in the specific immune response to the oxidized glycoprotein in the pre- and post-treatment samples.

Determination of antibody production against administered therapeutic

Growing community of inventors

Winchester, MA, United States of America

Mary E White-Scharf